Catalyst Pharmaceutical Partners Announces First Quarter 2012 Financial Results
CORAL GABLES, Fla., May 16, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the three month period ended March 31, 2012. The Company reported a net loss of $1,089,186, or $0.04 per basic and diluted share, compared to a net loss of $1,517,136, or $0.08 per basic and diluted share, for the same period in 2011. Research and development expenses for the first quarter of 2012 were $727,327, compared to $903,953 in the first quarter...continuedCPRX Drugs addiction addict
Related News:
- Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2011 Financial Results
- Cobalt International Energy, Inc. Announces Fourth Quarter and Year-End 2011 Results and Announces Successful Deepwater Gulf of Mexico Appraisal Well
- CIC Energy Reports First Quarter 2012 Financial Results
- BMTC Group Inc. announces financial results for its quarter ended March 31st, 2012
- Resinco Capital Partners Inc. Releases Q1 2012 Results and Provides Loan Facility
- Greenlight Re Announces First Quarter 2012 Financial Results
- Cheniere Energy Reports Fourth Quarter and YE 2011 Results
Shengtai Pharmaceutical, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results
WEIFANG, China, May 16, 2012 /PRNewswire-Asia/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "we" or "us"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the third quarter of fiscal 2012 ended March 31, 2012. Third Quarter Fiscal Year 2012 Result of Operations Net sales for the three months ended March 31, 2012 were $3...continuedSGTI Healthcare Drugs
Related News:
- Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results
- Shengtai Pharmaceutical, Inc. Establishes Special Committee to Evaluate Non-binding Going Private Proposal
- Pomerantz Law Firm Investigates Claims on Behalf of Investors of Shengtai Pharmaceutical, Inc.
- Rigrodsky & Long, P.A. Announces Investigation Of Shengtai Pharmaceutical, Inc. Going Private Proposal
- The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Shengtai Pharmaceutical, Inc. in Connection with the Receipt of a Going Private Proposal
- Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
- China Pharma Holdings, Inc. to Report Fiscal Year 2011 Financial Results on March 15, 2012
Akela Pharma reports financial results for the three months ended March 31, 2012
AUSTIN, TX, May 15, 2012 /CNW Telbec/ - Akela Pharma, Inc. ("Akela"), (TSX: AKL), an industry leader in providing pharmaceutical contract dosage development and clinical and commercial manufacturing, today announced its financial results for the three months ended March 31, 2012. Total consolidated revenues for the three months ended March 31, 2012 were $0.8 million in contract services, as compared to $4.2 million, including $3.5 million of contract services, for 2011. Consolidated net loss ...continuedAKL:CA Drugs Healthcare
Related News:
- Akela Pharma reports financial results for the year ended 2011
- Akela Pharma reports financial results for the year ended 2011
- Innovaro, Inc. Reports Financial Results for Three Months Ended March 31, 2012
- Daily Journal Corporation Announces Financial Results for the Six Months ended March 31, 2012
- Sonor Investments Limited Reports Financial Results for the Year Ended December 31, 2011 and Three Months Ended March 31, 2012
- Badger Daylighting Ltd. Announces Results for the Three Months Ended March 31, 2012
- Patterson-UTI Energy Reports Financial Results for Three Months Ended March 31, 2012
Silvermex Resources Announces Q1 2012 Financial Results
VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 15, 2012) - Silvermex Resources Inc. ("Silvermex") (TSX:SLX) reported today its unaudited financial results for the quarter ended March 31, 2012. Highlights from the quarter, which should be read in conjunction with the unaudited financial statement and management's discussion and analysis available at www.silvermexresources.com and www.sedar.com, include: The Company entered into a definitive agreement with First Majestic Silver Corp. ("First M...continuedSLX:CA Drugs Healthcare
Related News:
- First Majestic Announces Friendly Acquisition of Silvermex Resources
- Silvermex Aims to Deliver Resource and Production Growth in 2012
- Silvermex Reports Positive Financial Performance for the Year 2011
- Silvermex Reports Positive Financial Performance for the Year 2011
- Silvermex Files Form 40-F Registration Statement With the SEC
- Silvermex Intersects High Grade Gold at La Guitarra-306.99 g/t Au and 1,033.60 g/t Ag or 18,225 g/t Silver Equivalent Over 1.45 Meters
- Maxim Power Corp. Announces 2012 First Quarter Financial and Operating Results
Nile Therapeutics Reports 2012 First Quarter Financial Results
SAN FRANCISCO, May 15, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its first quarter financial results for 2012. For the first quarter of 2012, Nile reported a net operating loss of $0.8 million, or $0.02 per share. Weighted-average shares outstanding for the quarter were 39.7 million. Nile reported collaboration income of $0.2 million during the quarter ended March...continuedNLTX Drugs Healthcare
Related News:
- Nile Therapeutics Announces Positive Clinical Trial Results Evaluating the Subcutaneous Infusion of Cenderitide
- Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
- Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering
- Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
- Blue Nile Announces Fourth Quarter and Fiscal Year 2011 Financial Results
- Trius Therapeutics Reports Fourth Quarter and Year End 2011 Financial Results
- United Therapeutics Corporation Reports First Quarter 2012 Financial Results
BELLUS Health Securityholders Vote in Favour Of $17.25 Million Strategic Transaction with Pharmascience
- BELLUS Health reports results for the first quarter ended March 31, 2012, and provides corporate update - LAVAL, QC, May 15, 2012 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") today conducted its Annual and Special Meeting of Securityholders in relation to the $17.25 million strategic transaction and financing with Pharmascience Inc. ("Pharmascience") announced on April 5, 2012. The Company also reported its financial results for the first quarter ended Marc...continuedBLU:CA BLUS Drugs Drugs Healthcare
Related News:
- Health Care REIT, Inc. Announces $508 Million of First Quarter 2012 Acquisitions
- Fitch Rates Memorial Health Services (CA) Series 2012A Bonds ‘AA-’; Outlook Stable
- Shareholders of iPerceptions Vote in Favour of the Amalgamation With XPND
- The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Catalyst Health Solutions Inc. in Connection with the Sale of the Company to SXC Health Solutions, Corp.
- The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Catalyst Health Solutions Inc. in Connection with the Sale of the Company to SXC Health Solutions, Corp.
- Health Net Reports Fourth Quarter 2011 GAAP Net Income of $60.2 Million, or $0.71 Per Diluted Share
- Metropolitan Health Networks Reports 2011 Results of Operations
ABMC Reports First Quarter 2012 Results
American Bio Medica Corporation (ABMC.PK) today announced financial results for the three months ended March 31, 2012. Net sales for the first quarter of 2012 were $2,296,000, an increase of $249,000, or 12.2%, when compared to net sales of $2,047,000 for the first quarter of 2011. Operating loss for the first quarter of 2012 was $169,000, compared to an operating loss of $374,000 in the first quarter of 2011. Net loss for the first quarter of 2012 was $206,000, or $0.01 per share, compared to a n...continuedABMC Healthcare Drugs usb
Related News:
- ABMC Reports Fourth Quarter and Year End 2011 Results
- Furniture Brands International Reports First Quarter 2012 Financial Results
- Katy Industries, Inc. Reports 2012 First Quarter Results
- Tembec reports financial results for its first quarter ended December 24, 2011
- Phoenix Footwear Reports First Quarter 2012 and 2011 Year End Results
- Alterra Capital Reports First Quarter 2012 Results
- Capitol Bancorp Reports First Quarter Results
Nymox Reports First Quarter 2012 Financial Results
HASBROUCK HEIGHTS, N.J., May 15, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2012. Nymox reported a net loss of $1,846,974, or $0.06 per share for the quarter ended March 31, 2012, compared to $4,431,091, or $0.14 per share for the quarter ended March 31, 2011. Net losses include stock-based compensation charges of $51,496 in the quarter ended March 31, 2012 and $3,583,258 in the comparative period in 2011. The ...continuedNYMX dementia Healthcare Drugs
Related News:
- Nymox Reports 2011 Financial Results
- Critical Outcome Technologies Inc. Reports Fiscal 2012 Third Quarter Financial Results
- Green Plains Reports First Quarter 2012 Financial Results
- Isotechnika Reports First Quarter 2012 Financial Results
- Comstock Resources, Inc. Reports First Quarter 2012 Financial and Operating Results
- Palomar Medical Reports Financial Results for First Quarter 2012
- First Savings Financial Group, Inc. Reports 2012 Second Quarter Financial Results
Installation of 3M ACCR in Siberia Boosts Electric Power To City of Irkutsk without Need for Larger Towers
Utility Upgrades Key Overhead Line with Breakthrough Conductor, Nearly Doubling Capacity to Accommodate Growing Demand Already in use on four continents in a broad range of harsh climates, 3M ACCR (Aluminum Conductor Composite Reinforced) has now been installed in Siberia, serving one of the region’s largest cities, Irkutsk. Irkutsk Electronetwork Co. (IESK) chose the breakthrough overhead conductor as a way to avoid tower construction or right-of-way expansion while nearly doubling power...continuedMMM Drugs market mine
Related News:
- Guadalupe Valley Electric Cooperative Installs 3M ACCR to Boost Capacity on Line near San Antonio
- Eni teams up with Russians in Siberia
- Research and Markets: Transmission Towers for Electric Power Market Is Expected To Grow At A CAGR Of 7.9% from 2010 To 2020
- El Paso Electric Files Rate Case as Ordered by the El Paso City Council
- CODA Automotive Selects Mr. Electric as Preferred EV Charging Station Installation Partner
- TNK-BP accused of environmental neglect
- S&C Electric Company, EPB and the U.S. Dept. of Energy reach smart grid installation milestone
International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene and Cell Therapy 15th Annual Meeting
International Stem Cell Corporation (OTCBB: ISCO) (www.internationalstemcell.com) today announced that several of its leading scientists will present experimental results from three of ISCO’s pre-clinical therapeutic programs. Firstly, the application of A9 dopaminergic neurons derived from human parthenogenetic stem cells (hpSC) for the treatment of Parkinson’s disease. Demonstrating functional dopaminergic neurons in vivo represents an important milestone towards the goal of crea...continuedISCO stemcell Drugs cells
Related News:
- ISCO Scientists to Present Results of Recent Stem Cell Research on Parkinson’s Disease at Annual Meeting of American Academy of Neurology
- International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support its Therapeutic Programs
- International Stem Cell Corporation Announces 2011 Financial Results
- International Stem Cell Corporation Appoints MZ Group as its Investor Relations Firm
- International Stem Cell Corporation Announces 2011 Financial Results
- ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE Cells
- Scientists Report that Process of Converting Non-Beating Heart Cells into Functional, Beating Heart Cells is Enhanced Using Thymosin Beta 4 in Conjunction with Gene Therapy
Natural Alternatives International, Inc. Announces Fiscal 2012 Q3 and YTD Results
-- Continued Increase in Net Sales and Income from Operations -- Posts 13th Consecutive Quarter of Profitability SAN MARCOS, Calif., May 14, 2012 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $1.1 million or $0.15 per diluted share on net sales of $17.4 million for the quarter ended March 31, 2012. These results included a full effective tax...continuedNAII validation Drugs Healthcare
Related News:
- United Natural Foods, Inc. Announces Second Quarter Fiscal 2012 Results
- Xilinx Announces Q3 Fiscal 2012 Results
- SIFCO Industries, Inc. Announces Fiscal 2012 First Quarter Financial Results
- Korn/Ferry International Announces Third Quarter Fiscal 2012 Results of Operations
- HNI Corporation Announces Improved Results For First Quarter Fiscal 2012
- F5 Networks Announces Results for Second Quarter of Fiscal 2012
- CVTech Group Inc. reports its financial results for the 1st quarter of fiscal 2012 and announces review of strategic alternatives
ProMetic Reports Its First Quarter 2012 Highlights and Financial Results
- Secured business for 2012 now exceeds $21 million; points to progressively stronger quarters - $4.4 million of cash received to date from upfront payments and equity investments - $1.1 million of revenue recognized in the first quarter LAVAL, QUEBEC, CANADA--(Marketwire - May 14, 2012) - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic" or the "Corporation") today reported its financial results and highlights for the first quarter of 2012. All amounts are in Canadian dollars unless otherwise...continuedPLI:CA Drugs Healthcare
Related News:
- ProMetic Reports Its Year End 2011 Highlights and Financial Results
- ProMetic Reports Highlights of its 2012 Annual and Special Meeting of Shareholders
- ShareFEST 2012 Highlights Collaboration and Compliance in the Life Science Enterprise
- Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
- Sun Life Financial Reports First Quarter 2012 Results
- Ally Financial Reports Preliminary First Quarter 2012 Financial Results
- SeraCare Reports 9 Percent Revenue Growth in First Quarter Fiscal Year 2012
Critical Alerts For Home Depot, Dow Chemical, Baidu, Rio Tinto, and Perrigo Co. Released By InvestorsObserver
CHICAGO, May 14, 2012 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HD, DOW, BIDU, RIO, and PRGO. To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/51120121 (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Home Depot Inc. (NYSE: HD), Dow Chemical Company (NYSE: DOW), Baidu Inc. (Nasda...continuedBIDU DOW HD PRGO RIO Drugs Retail ethics
Related News:
- Critical Alerts For JP Morgan, CA Technologies, St Jude Medical, Bed Bath & Beyond, and Sina Corp. Released By InvestorsObserver
- Critical Alerts For Morgan Stanley, J C Penney, TJX Companies, Cigna, and Dicks Sporting Goods Released By InvestorsObserver
- Critical Alerts For Exxon Mobil, Goldcorp, American Eagle Outfitters, Ryland, and H&R Block Released By InvestorsObserver
- Critical Alerts For Caterpillar, Lowes, DISH Network, Zions Bancorp., and Sohu.com Released By InvestorsObserver
- Critical Alerts For NVIDIA, Ingersoll Rand, Sotheby’s, Nuance Communications, and Regeneron Pharmaceuticals Released By InvestorsObserver
- Critical Alerts For MasterCard, Celgene, Tempur-Pedic, AstraZeneca, and Sotheby’s Released By InvestorsObserver
- Critical Alerts For Macy’s, Avis, Rackspace, Stone Energy, and Jazz Pharmaceuticals Released By InvestorsObserver
Corgenix Reports Record Quarterly Sales Results
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its third quarter Form 10-Q and reported its financial results. The report disclosed that the company’s revenues increased substantially, both for the quarter and year to date. However, due to the current product mix, gross margins decreased resulting in a slightly larger net loss for the quarter. Some of the results highlighted by the report are as follows: Revenues for ...continuedCONX pharmaceuticals Healthcare Drugs
Related News:
- Corgenix to Host Conference Call to Discuss Second Quarter Results
- Orchids Paper Products Company Reports Record Quarterly Converted Product Sales and 2011 Results
- Olympic Steel Reports Record Quarterly Sales and First Quarter 2012 Financial Results
- Wabtec Reports Record Quarterly Sales and Earnings; 1Q EPS of $1.22, Up 44 Percent
- CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
- Starcore Reports Record Quarterly Earnings of $3.2 Million for First Quarter of 2012
- Armanino Foods of Distinction, Inc. Reports Second Highest Quarterly Sales in Its History and Record First Quarter Profits
Microbix reports strong second quarter results
Quarterly Revenues Increase 8%; Sales up 31% in Last 6 Months; Pipeline Products Move Closer to Final Funding Arrangements TORONTO, May 14, 2012 /CNW/ - Microbix Biosystems Inc. (TSX: MBX), a biotechnology company commercializing virology and novel biotechnologies, today reported strong financial results for the second quarter of fiscal 2012. For the quarter ended March 31, 2012, Microbix reported revenues of $1,896,947 an 8% increase from $1,761,905 for the same quarter in 2011....continuedMBX:CA Healthcare Drugs
Related News:
- Microbix Reports Very Strong First Quarter Results
- FirstService Reports Strong Fourth Quarter and Full Year Results
- Astral reports strong first quarter results for Fiscal 2012
- Santa Fe Gold Reports Strong Operating Results for March 2012 Quarter
- High Liner Foods Reports Strong Operating Results for the Fourth Quarter and Record Year for 2011
- Neiman Marcus, Inc. Reports Second Quarter Earnings
- Attunity Reports Fourth Quarter and Full Year 2011 Financial Results
MethylGene Reports First Quarter 2012 Financial Results and Provides an Update on Clinical Programs
MONTREAL, QUEBEC--(Marketwire - May 14, 2012) - MethylGene Inc. (TSX:MYG) today reported financial results for the first quarter ended March 31, 2012 and provided an update on clinical programs. Highlights Rachel W. Humphrey, MD was appointed as Executive Vice President and Chief Medical Officer on January 4, 2012. During this quarter, we strengthened our Board of Directors with the appointments of Henry J. Fuchs MD and Peggy Mulligan FCA. Our MGCD290 Phase II clinical trial and MGC...continuedMYG:CA Drugs Healthcare
Related News:
- MethylGene Reports Fourth Quarter and Full Year 2011 Financial Results
- Synta Provides Clinical Update and Reports Fourth Quarter and Year End 2011 Financial Results
- Synta Provides Clinical Update and Reports Fourth Quarter and Year End 2011 Financial Results
- Incyte Reports 2011 Fourth-Quarter and Full-Year Financial Results; Provides 2012 Financial Guidance; Updates Shareholders on Key Clinical Programs
- Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
- Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results and Provides Pipeline Update
- BioCryst Provides Corporate Update and Reports First Quarter 2012 Financial Results
USANA Procosa Receives ConsumerLab.com Certification
Third-Party Testing Company Approves USANA's Joint Health Product SALT LAKE CITY, May 14, 2012 /PRNewswire/ -- USANA Health Sciences, Inc. (NYSE: USNA), a global nutritional supplements company, today announced that its USANA ® Procosa supplement, which promotes optimal joint health, has been tested and approved by ConsumerLab.com, LLC, a company that independently tests health products to help consumers and healthcare professionals make safe purchasing decisions. ConsumerLab.com previously a...continuedUSNA Drugs Healthcare usana
Related News:
- USANA( Probiotic Receives ConsumerLab.com Certification
- USANA and US Speedskating Team Extend Partnership
- USANA Schedules First Quarter Earnings Release and Conference Call
- USANA Schedules Fourth Quarter and Full-Year Earnings Release and Conference Call
- USANA Health Sciences Announces Fourth Quarter and Full-Year 2011 Financial Results
- Zappos Fulfillment Centers, Inc. Receives "SHARP" Safety Certification by the Kentucky Labor Cabinet
- IO Receives SSAE 16 Type 2 Certification for Modular Data Centers
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
CRANBURY, N.J., May 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2012. Palatin reported a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the quarter ended March 31, 2012, compared to a net loss of $3.8 mill...continuedPTN pharma biotech Drugs
Related News:
- Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be Held on February 15, 2012
- Critical Outcome Technologies Inc. Reports Fiscal 2012 Third Quarter Financial Results
- Teletouch Reports Third Quarter 2012 Fiscal Year Results
- OPNET Technologies, Inc. Schedules Fiscal 2012 Fourth Quarter Results Teleconference/Webcast for Monday, May 14, 2012
- GT Advanced Technologies Inc. Announces Third Quarter Fiscal Year 2012 Results
- Alliance One International Reports Fiscal Year 2012 Third Quarter Results
- CA Technologies Reports Third Quarter Fiscal Year 2012 Results
PetroMagdalena announces shares for debt issuance
TORONTO, May 14, 2012 /CNW/ - PetroMagdalena Energy Corp. (TSXV: PMD) announced today that it has entered into an agreement to issue shares to settle certain debt owed to Pacific Rubiales Energy Corp. in connection with the exploration programs at the Topoyaco, Arrendajo and Las Quinchas blocks. Luciano Biondi, Chief Executive Officer of the Company stated: "This debt settlement transaction preserves our working capital and cash balance, and improves our capital structure. Existing cash balances ...continuedPMD.WT:CA PMD:CA Healthcare Drugs
Related News:
- PetroMagdalena announces shares for debt issuance
- PetroMagdalena completes shares for debt Issuance
- PetroMagdalena completes shares for debt Issuance
- Copper Fox announces the issuance of 1,272,727 shares for outstanding debt settlement
- PetroMagdalena provides exploration and production update including new discoveries at Cubiro and Arrendajo
- PetroMagdalena provides exploration and production update including new discoveries at Cubiro and Arrendajo
- PetroMagdalena announces exploration update
PetroMagdalena announces shares for debt issuance
TORONTO, May 14, 2012 /PRNewswire/ - PetroMagdalena Energy Corp. (TSXV: PMD) announced today that it has entered into an agreement to issue shares to settle certain debt owed to Pacific Rubiales Energy Corp. in connection with the exploration programs at the Topoyaco, Arrendajo and Las Quinchas blocks. Luciano Biondi, Chief Executive Officer of the Company stated: "This debt settlement transaction preserves our working capital and cash balance, and improves our capital structure. Existing cash ba...continuedPMD.WT:CA PMD:CA Drugs Healthcare
Related News:
- PetroMagdalena announces shares for debt issuance
- PetroMagdalena completes shares for debt Issuance
- PetroMagdalena completes shares for debt Issuance
- Copper Fox announces the issuance of 1,272,727 shares for outstanding debt settlement
- PetroMagdalena provides exploration and production update including new discoveries at Cubiro and Arrendajo
- PetroMagdalena provides exploration and production update including new discoveries at Cubiro and Arrendajo
- PetroMagdalena announces exploration update
IIROC Trading Halt – CTI
VANCOUVER, May 11, 2012 /CNW/ - The following issues have been halted by IIROC: Company: Caiterra Intl Energy Corp. TSX-Venture Symbol: CTI Reason: Cease Trade Order Halt Time (ET): 9:00 AM ET The Investment Industry Regulatory Organization of Canada (IIROC) can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the company. Trading halts are issued based on the principl...continuedCTI:CA Healthcare Drugs
Related News:
- IIROC Trading Halt – PKE
- IIROC Trading Halt – CRS
- IIROC Trading Halt – ALO
- IIROC Trading Halt – ACX
- IIROC Trading Halt – REL
- IIROC Trading Halt – CNK
- IIROC Trading Halt – FIS
Osiris Therapeutics Reports First Quarter 2012 Financial Results
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and commercializing products to treat medical conditions in inflammatory, cardiovascular, orthopedic, and wound healing markets, announced today its results for the first quarter ended March 31, 2012. Highlights and Recent Developments Strong demand for Grafix® and Ovation® fuels Biosurgery revenue growth to $1.14 million for the quarter - an increase of 49% over the previous quarter. ...continuedOSIR Drugs stemenhance meniscus
Related News:
- Osiris Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results
- Osiris Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results
- Osiris Therapeutics Announces Fourth Quarter and Full Year 2011 Financial Results Conference Call
- Adherex Reports Recent Developments and First Quarter March 31, 2012 Financial Results
- Lonestar reports 2012 first quarter financial results
- Acorda Therapeutics Reports First Quarter 2012 Financial Results
- S&W Announces Results for the Third Quarter Ended March 31, 2012
Adherex Reports Recent Developments and First Quarter March 31, 2012 Financial Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - May 11, 2012) - Adherex Technologies Inc. (TSX:AHX)(PINKSHEETS:ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results and recent developments for the first quarter ended March 31, 2012. All amounts are in U.S. dollars unless otherwise specified. Recent Developments Eniluracil Phase 2 Study Update - Enrollment in the Company's Phase II clinical trial for ...continuedADHXF AHX:CA Healthcare Drugs
Related News:
- Adherex Reports Recent Developments and Fiscal Year Ended December 31, 2011 Financial Results
- Cardium Presents Fourth Quarter and Year-End 2011 Financial Results and Recent Developments
- Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
- OxySure to Hold Conference Call to Discuss FY2011 Financial Results and Recent Developments
- MI Developments Announces 2012 First Quarter Results
- Discovery Labs Reports Fourth Quarter Financial Results and Highlights Recent Milestones
- Delcath Highlights Fiscal 2011 Fourth Quarter and Full Year Results and Recent Developments
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
MISSISSAUGA, ON, May 11, 2012 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) , a drug development company advancing a diverse portfolio of hematology and cancer related products, today reported operational and financial results for its third quarter of fiscal 2012, ended March 31, 2011. "In the past few months we delivered robust Phase I/II results for our JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis and we raised an additional $80 million principally to support the further...continuedYM:CA YMI Drugs pharmingen Healthcare
Related News:
- YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
- Critical Outcome Technologies Inc. Reports Fiscal 2012 Third Quarter Financial Results
- Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results
- Kirkland Lake Gold Inc.: Fiscal 2012 Third Quarter Financial and Operational Results; Expansion to 2,200 Tons of Ore Per Day to Be Accelerated
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
MISSISSAUGA, ON, May 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) , a drug development company advancing a diverse portfolio of hematology and cancer related products, today reported operational and financial results for its third quarter of fiscal 2012, ended March 31, 2011. "In the past few months we delivered robust Phase I/II results for our JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis and we raised an additional $80 million principally to support the ...continuedYM:CA YMI pharmaceuticals Drugs pharmingen
Related News:
- YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
- Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results
- Critical Outcome Technologies Inc. Reports Fiscal 2012 Third Quarter Financial Results
- Hanwei Energy Services Reports Third Quarter Fiscal 2012 Financial and Operational Results